144O Comparison of efficacy and safety of paclitaxel and capecitabine followed by capecitabine as maintenance therapy versus cisplatin and capecitabine therapy for advanced gastric cancer: a multicentre, randomised, active-controlled phase III study

Xuan Zhang(Lanzhou Veterinary Research Institute), J. Feng(Hangzhou First People's Hospital), Bing Hu(University of Waterloo), Wei Liu(Hebei Medical University), Jian Xu(University of California, Los Angeles), Qing Fan(Chongqing University), Zhihao Lü(Nanjing Tech University), Wei Bai(Chinese Academy of Medical Sciences & Peking Union Medical College), Yue Pan(Shandong University), W. Li(Jilin University), Lin Shen(Peking University), Yongqian Shu(Jiangsu Province Hospital), W. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuxian Bai(Harbin Medical University), Tianshu Liu(Sun Yat-sen University), Guanghai Dai(Chinese PLA General Hospital), Qinghua Xu(Anhui Academy of Medical Sciences), Nengwen Xu(Zhejiang University), Liyan Xia(People 's Hospital of Jilin Province), Yong Gao(Shanghai East Hospital)
Annals of Oncology
December 1, 2015
10.1093/annonc/mdv523.05
Cited by 1

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821